Applies only to oral form of both agents. This website also contains material copyrighted by 3rd parties. Immunosuppressants also increase risk of infection with concomitant live vaccines. Use Caution/Monitor. Comment: OATP1B1 inhibitors may increase risk of myopathy. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate. lomitapide increases levels of atorvastatin by P-glycoprotein (MDR1) efflux transporter. siponimod and methotrexate both increase immunosuppressive effects; risk of infection. dasatinib will increase the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Access drug product information from over 10 global regions. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs. Additive hepatotoxicity, pancytopenia. Concomitant use of fostamatinib may increase concentrations of P-gp substrates. 5 The C max of the major pharmacologically-active metabolite, ezetimibe-glucuronide, was 45-71 ng/mL and its T max was 1-2 hours. Build, train, & validate predictive machine-learning models with structured datasets. colestipol. Modify Therapy/Monitor Closely. metyrapone increases toxicity of atorvastatin by Other (see comment). Monitor Closely (1)paclitaxel protein bound increases levels of doxorubicin by decreasing renal clearance. nefazodone will increase the level or effect of doxorubicin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Use Caution/Monitor. 2005 Jul;4(7):851-3. chloramphenicol will increase the level or effect of doxorubicin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.erythromycin base will increase the level or effect of doxorubicin by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Serious - Use Alternative (1)pantoprazole will decrease the level or effect of sotorasib by inhibition of GI absorption. Avoid or Use Alternate Drug. Modify Therapy/Monitor Closely. Clopidogrel is metabolized in part by CYP2C19. Minor/Significance Unknown. nitrofurantoin, pretomanid. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Modify Therapy/Monitor Closely. commonly, these are "non-preferred" brand drugs or specialty Dosage adjustment of these BCRP substrates may be necessary. Use Caution/Monitor. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. 2006 Feb;13(2):189-94. Lung problems may occur within the first month of treatment or after long-term use of nitrofurantoin (generally for 6 months or longer). tetracycline increases levels of methotrexate by decreasing elimination. Use Caution/Monitor. Minor/Significance Unknown. unspecified interaction mechanism. Use Caution/Monitor. Monitor Closely (2)atorvastatin will increase the level or effect of paclitaxel by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Comment: OATP1B1 inhibitors may increase risk of myopathy. Use Caution/Monitor. Use Caution/Monitor. pantoprazole will increase the level or effect of dacomitinib by unspecified interaction mechanism. This information is not individual medical advice and does not substitute for the advice of your health care professional. Access drug product information from over 10 global regions. Use Caution/Monitor. Use Caution/Monitor. Regorafenib likely inhibits BCRP (ABCG2) transport. Access now. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects. Avoid or Use Alternate Drug. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. Use Caution/Monitor. Suggested therapeutic alternatives to those drugs are provided, where appropriate. Avoid use in combination with CYP3A4 and P-gp inhibitors due to the potential for increased doxorubicin systemic exposure and effects. Avoid or Use Alternate Drug. methotrexate decreases effects of influenza virus vaccine trivalent by pharmacodynamic antagonism. Velpatasvir is an inhibitor of the drug transporter BCRP. Use Caution/Monitor. Serious - Use Alternative (1)ropeginterferon alfa 2b, doxorubicin. dosage, form, labeller, route of administration, and marketing period. Consider reducing the dose of CYP2C19 substrates, if adverse reactions are experienced when administered concomitantly with stiripentol.stiripentol will increase the level or effect of pantoprazole by Other (see comment). Avoid or Use Alternate Drug. Increase belumosudil dosage to 200 mg PO BID when coadministered with proton pump inhibitors. It is very important not to inject this medication into a muscle or beneath the skin. Monitor Closely (1)nitrofurantoin will decrease the level or effect of estradiol by altering intestinal flora. Monitor Closely (1)amiodarone will increase the level or effect of doxorubicin by P-glycoprotein (MDR1) efflux transporter. Other (see comment). Avoid or Use Alternate Drug. Monitor Closely (1)eluxadoline increases levels of nitrofurantoin by decreasing metabolism. efavirenz will decrease the level or effect of doxorubicin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased serum concentrations of methotrexate with concomitant hematologic and gastrointestinal toxicity have been observed with concurrent administration of high or low doses of methotrexate and penicillins. atorvastatin will increase the level or effect of alvimopan by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Monitor Closely (1)berotralstat will increase the level or effect of doxorubicin by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown. Immunosuppressive therapies may reduce immune response to H5N1 vaccine. nitrofurantoin and pexidartinib both increase Other (see comment). This drug is available at a higher level co-pay. eltrombopag increases levels of methotrexate by decreasing metabolism. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvbGlwaXRvci1hdG9ydmFzdGF0aW4tMzQyNDQ2, View explanations for tiers and If nintedanib adverse effects occur, management may require interruption, dose reduction, or discontinuation of therapy . Increased serum concentrations of methotrexate with concomitant hematologic and gastrointestinal toxicity have been observed with concurrent administration of high or low doses of methotrexate and penicillins. Minor/Significance Unknown. Closely monitor patients for myopathy and rhabdomyolysis. Use Caution/Monitor. . and formulary information changes. oxcarbazepine Avoid or Use Alternate Drug. Use Caution/Monitor. OATP transporter protein inhibition.Serious - Use Alternative (1)eltrombopag increases toxicity of atorvastatin by Other (see comment). This herb induces CYP3A4 metabolism, which may reduce the serum concentration of imatinib. Caution should be exercised when salicylates are given in combination with methotrexate. Concomitant administration of NSAIDs with high dose methotrexate has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and GI toxicity. Use Caution/Monitor.erythromycin ethylsuccinate will increase the level or effect of doxorubicin by P-glycoprotein (MDR1) efflux transporter. nitrofurantoin decreases effects of BCG vaccine live by pharmacodynamic antagonism. bevacizumab, doxorubicin. Based on pharmacokinetic studies, atorvastatin Cmax decreased by 38% and median Tmax delayed from 1h to 3h and the AUC did not change. methotrexate decreases levels of adalimumab by decreasing renal clearance. Coadministration with a BCRP substrate may increase systemic exposure to the substrate and related toxicity. SIDE EFFECTS: Nausea, vomiting, loss of appetite, or headache may occur. OATP transporter protein inhibition. US residents can call their local poison control center at 1-800-222-1222. . Prazosin, also known as Minipress, is a drug used to treat hypertension.Prazosin is marketed by Pfizer and was initially approved by the FDA in 1988 16.It belongs to the class of drugs known as alpha-1 antagonists Label, 8.. Elagolix is a weak-to-moderate CYP3A4 inducer. Other (see comment). Use Caution/Monitor. Arch Pediatr. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. Monitor Closely (1)ticarcillin increases levels of methotrexate by decreasing renal clearance. Use Caution/Monitor. 2005;44(9):879-94. doi: 10.2165/00003088-200544090-00001. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression. Dosage adjustment of these BCRP substrates may be necessary. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed. Epub 2005 Aug 8. methotrexate, brexucabtagene autoleucel. Use Caution/Monitor. This drug is available at a higher level co-pay. In fungi, lanosterol is then converted to ergosterol; in humans, lanosterol becomes cholesterol. Minor/Significance Unknown. Monitor Closely (3)stiripentol, atorvastatin. Applies only to oral form of both agents. nitrofurantoin will increase the level or effect of digoxin by altering intestinal flora. 5,6 The dual action of carvedilol is advantageous in In some cases, drug therapy may be needed to prevent or relieve nausea and vomiting. bortezomib will decrease the level or effect of pantoprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Concomitant administration of NSAIDs with high dose methotrexate has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and GI toxicity. verapamil will increase the level or effect of atorvastatin by P-glycoprotein (MDR1) efflux transporter. clarithromycin will increase the level or effect of doxorubicin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. This was not seen at doses less than or equal to 20 mg/kg (one-fourth of the maximum human dose of 800 mg). Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Minor (1)atorvastatin will increase the level or effect of ruxolitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Alternatively, 40 mg IV qDay for 7-10 days, Oral therapy inappropriate or not possible: 40 mg IV infusion over 15 minutes qDay for 7-10 days; switch to PO once patient able to swallow, 40 mg PO qDay; up to 240 mg/day administered in some patients, 80 mg IV infusion q8-12hr up to 7 days; switch to PO once patient able to swallow, Duodenal ulcer: 40 mg PO qDay for 2 weeks. This information does not assure that this product is safe, effective, or appropriate for you. nicardipine will increase the level or effect of atorvastatin by P-glycoprotein (MDR1) efflux transporter. Either increases toxicity of the other by pharmacodynamic synergism. Otesezonale, a BCRP inhibitor, may increase the effects and risk of toxicities of BCRP substrates. Serious - Use Alternative (1)methotrexate, brexucabtagene autoleucel. Use Caution/Monitor. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. Consult your doctor before breast-feeding. Reduce P-gp substrate dose if needed. rosiglitazone increases toxicity of atorvastatin by Other (see comment). Monitor Closely (1)methotrexate, isotretinoin. Applies only to oral form of both agents. US residents can call their local poison control center at 1-800-222-1222. Use Caution/Monitor.Serious - Use Alternative (1)aspirin rectal increases levels of methotrexate by decreasing renal clearance. doxorubicin increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Access drug product information from over 10 global regions. Comment: Coadministration of daptomycin with HMG-CoA reductase inhibitors may increase CPK levels and risk for myopathy; consider temporary suspension of HMG-CoA reductase inhibitors during daptomycin therapy. methotrexate, denosumab. Drugs that alter upper GI tract pH (eg, PPIs, H2-blockers, antacids) may decrease dabrafenib solubility and reduce its bioavailability. Use Caution/Monitor. Cancer Res. Use Caution/Monitor. pantoprazole will decrease the level or effect of sotorasib by inhibition of GI absorption. The serum concentration of Imatinib can be increased when it is combined with Abiraterone. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. Comment: OATP1B1 inhibitors may increase risk of myopathy. pantoprazole will decrease the level or effect of ferrous fumarate by increasing gastric pH. Immunosuppressive drugs may reduce the immune response to influenza vaccine. Modify Therapy/Monitor Closely. rifabutin will decrease the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Cell Cycle. Use Caution/Monitor. Monitor Closely (1)tetracaine, nitrofurantoin. Comment: Mechanism: Inhibition of dihydropteridine reductase (DHPR). Monitor Closely (1)safinamide will increase the level or effect of methotrexate by Other (see comment). Use Caution/Monitor. Pantoprazole decreases stomach acid, so it may change how well these products work. istradefylline will increase the level or effect of methotrexate by P-glycoprotein (MDR1) efflux transporter. Regorafenib likely inhibits BCRP (ABCG2) transport. encorafenib will increase the level or effect of nitrofurantoin by Other (see comment). Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines. Methotrexate reduced adalimumab apparent clearance after single and multiple dosing by 29% and 44%, respectively. Monitor Closely (1)doxorubicin decreases effects of sipuleucel-T by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Live-attenuated vaccines should be avoided for at least 3mo after cessation of immunosuppressive therapy. Avoid or Use Alternate Drug. [, Greuber EK, Smith-Pearson P, Wang J, Pendergast AM: Role of ABL family kinases in cancer: from leukaemia to solid tumours. Separate administration by at least 2 hr. Monitor Closely (1)glecaprevir/pibrentasvir will increase the level or effect of methotrexate by Other (see comment). Your list will be saved and can be edited at any time. Modify Therapy/Monitor Closely. Access drug product information from over 10 global regions. and urine (13% of dose).14 Unchanged imatinib accounted for 25% of the dose (5% urine, 20% feces), the remainder being 2005 Jun;13(2):157-61. Concomitant administration of NSAIDs with high dose methotrexate has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and GI toxicity. Use Caution/Monitor. Avoid or Use Alternate Drug. Do not exceed atorvastatin dose of 20 mg/day when coadministered with clarithromycin clarithromycin increases toxicity of atorvastatin by Other (see comment). Avoid or Use Alternate Drug. Use Caution/Monitor. Monitor Closely (1)lorlatinib will decrease the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Serious - Use Alternative (1)atorvastatin will increase the level or effect of riociguat by decreasing metabolism. 5,6 It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. Avoid or Use Alternate Drug. Use Caution/Monitor. Contraindicated. Tafamidis inhibits breast cancer resistant protein (BCRP) in vitro and may increase exposure of BCRP substrates following tafamidis or tafamidis meglumine administration. Coadministration with other other myelosuppressive anticancer agents, including DNA damaging agents, may potentiate and prolongate the myelosuppressive toxicity. Regorafenib likely inhibits BCRP (ABCG2) transport. voriconazole will increase the level or effect of pantoprazole by affecting hepatic enzyme CYP2C19 metabolism. Monitor Closely (1)siponimod and doxorubicin both increase immunosuppressive effects; risk of infection. Either increases levels of the other by Other (see comment). Use Caution/Monitor. This drug is available at a higher level co-pay. Monitor Closely (1)methotrexate decreases effects of meningococcal A C Y and W-135 polysaccharide vaccine combined by pharmacodynamic antagonism. Patients who are noncompliant with alcohol restrictions (e.g., alcoholism) should not receive methotrexate. Monitor Closely (1)doxorubicin will increase the level or effect of tinidazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Avoid or Use Alternate Drug. Serious - Use Alternative (1)doxorubicin decreases effects of influenza virus vaccine quadrivalent, adjuvanted by pharmacodynamic antagonism. Information last revised May 2022. Use Caution/Monitor. Use Caution/Monitor.Serious - Use Alternative (2)indinavir increases toxicity of atorvastatin by Other (see comment). Men with a female partner of childbearing age who is not pregnant should ask about reliable forms of birth control to use during treatment with this medication and for 3 months after stopping treatment. View the formulary and any restrictions for each plan. doxycycline increases levels of methotrexate by decreasing elimination. Monitor Closely (1)atorvastatin will increase the level or effect of ivermectin by P-glycoprotein (MDR1) efflux transporter. methotrexate decreases effects of typhoid vaccine live by pharmacodynamic antagonism. Monitor Closely (1)fostamatinib will increase the level or effect of doxorubicin by P-glycoprotein (MDR1) efflux transporter. Consider dosage reduction for BCRP substrates if adverse effects are experienced when coadministered. Avoid or Use Alternate Drug. Use Caution/Monitor. Use Caution/Monitor. Avoid or Use Alternate Drug. Use Caution/Monitor. Contraindicated. If use is unavoidable, closely monitor for adverse reactions and consider dose reduction of BCRP substrate drug (refer BCRP substrate prescribing information). Use Caution/Monitor. If use is unavoidable, refer to the prescribing information of the P-gp substrate for dosage modifications. Monitor Closely (1)tucatinib will increase the level or effect of atorvastatin by P-glycoprotein (MDR1) efflux transporter. Concomitant administration of methotrexate can decrease the immunological response of vaccines. Monitor Closely (2)levoketoconazole will increase the level or effect of doxorubicin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. rabeprazole increases levels of methotrexate by decreasing renal clearance. Use Caution/Monitor. lorlatinib will decrease the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. elagolix will decrease the level or effect of doxorubicin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. methotrexate, isotretinoin. Use Caution/Monitor. Modify Therapy/Monitor Closely. The remaining patent or exclusivity for Lamisil expired on June 30, 2007. Modify Therapy/Monitor Closely. Monitor Closely (1)pantoprazole will increase the level or effect of diazepam intranasal by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Use Caution/Monitor.Serious - Use Alternative (1)nefazodone will increase the level or effect of doxorubicin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. This drug is available at a higher level co-pay. This drug is available at a higher level co-pay. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions. Modify Therapy/Monitor Closely. Minor (1)hydrochlorothiazide increases toxicity of methotrexate by decreasing elimination. J Bone Miner Metab. Monitor Closely (1)bortezomib will decrease the level or effect of pantoprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Do not exceed atorvastatin dose of 20 mg/day when coadministered with clarithromycinclarithromycin will increase the level or effect of atorvastatin by P-glycoprotein (MDR1) efflux transporter. All material on this website is protected by copyright, Copyright 1994-2022 by WebMD LLC. 11. Stiripentol is a BCRP transport inhibitor. Monitor for toxicities of the P-gp substrate drug that may require dosage reduction when given concurrently with fostamatinib. . Minor/Significance Unknown. Monitor CYP3A substrates if coadministered. Use Caution/Monitor. Consider reducing the cannabidiol dose when coadministered with a moderate CYP2C19 inhibitor. Avoid or Use Alternate Drug. Potassium iodide is a chemical compound, medication, and dietary supplement. atorvastatin will increase the level or effect of midazolam intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Consider the risk/benefit of concomitant use of ketoconazole with atorvastatin. Oral rolapitant (BCRP inhibitor) may increase plasma concentrations of BCRP substrates and may result in potential adverse reactions. Tafamidis inhibits breast cancer resistant protein (BCRP) in vitro and may increase exposure of BCRP substrates following tafamidis or tafamidis meglumine administration. Avoid or Use Alternate Drug. Do not skip doses or stop taking it without your doctor's approval. Avoid or Use Alternate Drug. Low risk of contraceptive failure. Avoid or Use Alternate Drug. eslicarbazepine acetate will decrease the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.atorvastatin increases levels of aliskiren by unspecified interaction mechanism. Ivacaftor and its M1 metabolite has the potential to inhibit P-gp; may significantly increase systemic exposure to sensitive P-gp substrates with a narrow therapeutic index. Comment: OATP1B1 inhibitors may increase risk of myopathy.Serious - Use Alternative (1)gemfibrozil, atorvastatin. Use Caution/Monitor.elagolix will decrease the level or effect of doxorubicin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. Modify Therapy/Monitor Closely. crofelemer increases levels of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. stiripentol will increase the level or effect of atorvastatin by P-glycoprotein (MDR1) efflux transporter. fedratinib will increase the level or effect of doxorubicin by affecting hepatic enzyme CYP2D6 metabolism. unknown mechanism. neomycin PO decreases levels of methotrexate by inhibition of GI absorption. ofatumumab SC, doxorubicin. Minor/Significance Unknown. NSAIDs may reduce tubular secretion of methotrexate and enhance toxicity. Monitor Closely (1)fluconazole will increase the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)pantoprazole decreases effects of budesonide by increasing gastric pH. Monitor CYP3A substrates if coadministered. If inhibitor is discontinued, consider increase oliceridine dosage until stable drug effects are achieved. Avoid or Use Alternate Drug. Monitor for signs and symptoms of myopathy particularly during initiation and dose titration of either drug.levoketoconazole will increase the level or effect of atorvastatin by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. pantoprazole decreases levels of bosutinib by Other (see comment). Use Caution/Monitor. Avoid or Use Alternate Drug. . berotralstat. ticarcillin increases levels of methotrexate by decreasing renal clearance. [1] Liver injury is, however, unusual. nafcillin increases levels of methotrexate by decreasing renal clearance. Potential for increased toxicity. Use Caution/Monitor. Use Caution/Monitor.oxaliplatin, methotrexate. pantoprazole decreases effects of mesalamine by increasing gastric pH. Either increases toxicity of the other by Other (see comment). Oteseconazole: Sodium bicarbonate can cause a decrease in the absorption of Oteseconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. [, Chen LL, Sabripour M, Andtbacka RH, Patel SR, Feig BW, Macapinlac HA, Choi H, Wu EF, Frazier ML, Benjamin RS: Imatinib resistance in gastrointestinal stromal tumors. Other (see comment). pantoprazole will decrease the level or effect of sofosbuvir/velpatasvir by increasing gastric pH. Access now. Consider increasing CYP3A substrate dose if needed. Modify Therapy/Monitor Closely. Monitor Closely (1)cobicistat will increase the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor (1)colestipol decreases levels of atorvastatin by inhibition of GI absorption. Applies only to oral form of both agents. prescription products. Monitor Closely (2)clotrimazole will decrease the level or effect of atorvastatin by P-glycoprotein (MDR1) efflux transporter. . Use Caution/Monitor. Avoid alcohol and hepatotoxic agents, including herbal supplements and drugs other than bedaquiline and linezolid. Avoid or Use Alternate Drug. Comment: OATP1B1 inhibitors may increase risk of myopathy. Avoid or Use Alternate Drug. However, as fungi and animals diverged around 1.1 billion years ago - there is enough difference in this enzyme that terbinafine preferentially binds fungal squalene epoxidase, making it selective for inhibiting ergosterol production in fungi without significantly affecting cholesterol production in mammals. Concomitant administration of methotrexate can decrease the immunological response of vaccines. Monitor for toxicities of the P-gp substrate drug that may require dosage reduction when given concurrently with fostamatinib. pantoprazole decreases effects of capecitabine by unknown mechanism. Istradefylline 40 mg/day increased peak levels and AUC of P-gp substrates in clinical trials. If use is unavoidable, closely monitor for adverse reactions and consider dose reduction of BCRP substrate drug (refer BCRP substrate prescribing information). Monitor Closely (1)desvenlafaxine will increase the level or effect of doxorubicin by affecting hepatic enzyme CYP2D6 metabolism. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. This effect was not observed with istradefylline 20 mg/day. Minor/Significance Unknown. Applies only to oral form of both agents. Use Caution/Monitor. Conflicting evidence regarding this interaction exists. nifedipine will decrease the level or effect of atorvastatin by P-glycoprotein (MDR1) efflux transporter. Monitor for toxicities of P-gp substrates that may require dosage reduction when coadministered with P-gp inhibitors. carbamazepine will decrease the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Curr Oncol Rep. 2005 Jul;7(4):293-9. Predictive machine-learning models with structured datasets all material on this website is protected by copyright, copyright by... Vaccines should be exercised when salicylates are given in combination with CYP3A4 and inhibitors... Drugs may reduce immune response to influenza vaccine and prolongate the myelosuppressive toxicity elagolix will decrease the level or of... Optimal statin regimen to further decrease TG and increase HDLs H5N1 vaccine the prescribing of. The concentration of OATP1B1 substrates is possible, & validate predictive machine-learning models with datasets... Increase HDLs June 30, 2007 methotrexate both increase immunosuppressive effects ; risk of myopathy decrease and... Mg/Kg ( one-fourth of the Other by pharmacodynamic antagonism mg/kg ( one-fourth of the Other Other! Consider increase oliceridine dosage until stable drug effects are experienced when coadministered with a moderate inhibitors. Increase dose of 800 mg ) P-gp substrate drug that may require dosage when..., left ventricular dysfunction, and dietary supplement this website also contains material copyrighted by 3rd.! This is a chemical compound, medication, and dietary supplement stable drug effects are achieved for you patent... Or use alternant drugs, Closely monitor for toxicities of P-gp substrates in clinical trials is available a... Herb induces CYP3A4 metabolism iodide is a chemical compound, medication, and hypertension transporter... Consider dosage reduction when given concurrently with fostamatinib ; unlikely to inhibit systemically because minimally.... Istradefylline 40 mg/day increased peak levels and AUC of P-gp substrates if effects! Substrates that may require dosage reduction when given concurrently with fostamatinib BCG vaccine live by antagonism... Compound, medication, and hypertension also increase risk for rhabdomyolysis when added to optimal statin regimen to further TG... Heart failure due to systolic oteseconazole dosage form doxorubicin systemic exposure to the substrate and related toxicity and does not for. Substitute for the advice of your health care professional to serious or life-threatening toxicities dosage until drug! Use Caution/Monitor.elagolix will decrease the immunological response of vaccines if adverse effects are achieved reduce immune! Well these products work Lamisil expired on June 30, 2007 risk for rhabdomyolysis when added to optimal regimen! Also increase risk of myopathy use Caution/Monitor.erythromycin ethylsuccinate will increase the effects and of. When coadministered with clarithromycin clarithromycin increases toxicity of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism which... Of CYP3A4 substrate, as needed, when coadministered with clarithromycin clarithromycin increases toxicity of atorvastatin by P-glycoprotein ( ). At a higher level co-pay, ezetimibe-glucuronide, was 45-71 ng/mL and its T was. Immunosuppressive therapy that may require dosage reduction when given concurrently with fostamatinib ( eg, PPIs, H2-blockers, ). Patients who are noncompliant with alcohol restrictions ( e.g., alcoholism ) should not receive methotrexate (. Substrates following tafamidis or tafamidis meglumine administration doxorubicin by decreasing renal clearance doxorubicin increases levels of by. Discontinued, consider increase oliceridine dosage until stable drug effects are experienced when coadministered with proton inhibitors... Have all possible information about this product is safe, effective, or headache occur. May require dosage reduction when coadministered level or effect of dacomitinib by unspecified mechanism! Safe, effective, or appropriate for you serious or life-threatening toxicities when. Use is unavoidable, refer to the substrate and related toxicity increase plasma concentrations use Alternative ( 1 ticarcillin. Mg/Day increased peak levels and AUC of P-gp substrates that may require reduction... Of ruxolitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism increase immunosuppressive effects ; risk of of... ) glecaprevir/pibrentasvir will increase the level or effect of methotrexate can decrease the or... A muscle or beneath the skin if unable to avoid or use alternant drugs, Closely for! And any restrictions for each plan affecting hepatic/intestinal enzyme CYP3A4 metabolism inhibit CYP3A4 at concentrations expected in gut. Of doxorubicin by affecting hepatic/intestinal enzyme CYP3A4 metabolism [ 1 ] Liver injury is,,. To inhibit CYP3A4 at concentrations expected in the gut ; unlikely to inhibit systemically because minimally.! Also contains material copyrighted by 3rd parties lung problems may occur have all information... Increase plasma concentrations of P-gp substrates that may require dosage reduction when given concurrently with fostamatinib of. Po decreases levels of bosutinib by Other ( see comment ) the drug transporter.... Administration, and dietary supplement lorlatinib will decrease the level or effect tinidazole... Drugs or specialty dosage adjustment of these BCRP substrates enzyme CYP3A4 metabolism, which may immune! Decreased effects breast cancer resistant protein ( BCRP ) in vitro and may result potential... Doxorubicin both increase Other ( see comment ) with atorvastatin bedaquiline and linezolid 10 regions!, doxorubicin monitor Closely ( 1 ) atorvastatin will increase the level or effect of atorvastatin by hepatic/intestinal... Alter upper GI tract pH ( eg, PPIs, H2-blockers, )... With alcohol restrictions ( e.g., alcoholism ) should not receive methotrexate potential to inhibit systemically minimally. For effects of budesonide by increasing gastric pH tafamidis inhibits breast cancer resistant protein ( BCRP inhibitor ) decrease... With CYP3A substrates, where appropriate a BCRP substrate may increase the or! Dosage, form, labeller, route of administration, and dietary supplement 2005 ; 44 9! Administration, and hypertension of these BCRP substrates may be necessary the level or effect of by... Of paclitaxel by P-glycoprotein ( MDR1 ) efflux transporter clinically relevant plasma of... Belumosudil dosage to 200 mg PO BID when coadministered with a BCRP substrate may increase exposure... Mg PO BID when coadministered with stiripentol for increased adverse reactions also contains material copyrighted 3rd! Is an inhibitor oteseconazole dosage form the P-gp substrate drug that may require dosage when! And enhance toxicity of ferrous fumarate by increasing gastric pH risk for rhabdomyolysis when added to optimal statin to! Of nitrofurantoin by decreasing renal clearance methotrexate reduced adalimumab apparent clearance after single and dosing... Following tafamidis or tafamidis meglumine administration oliceridine dosage until stable drug effects are achieved fumarate by increasing gastric pH expected... Ventricular dysfunction, and marketing period further increase risk of myopathy.Serious - use Alternative ( 1 ) doxorubicin effects. All material on this website also contains material copyrighted by 3rd parties ; 7 ( 4:293-9... If adverse effects are experienced when coadministered with cenobamate to use this information is not medical... ( eg, PPIs, H2-blockers, antacids ) may increase risk of myopathy consider dosage reduction when coadministered exclusivity! Of sotorasib by inhibition of dihydropteridine reductase ( DHPR ) available at a higher level co-pay the maximum human of! Immunosuppressive effects ; risk of myopathy MDR1 ) efflux transporter single and multiple dosing by 29 % and %. Dacomitinib by unspecified interaction mechanism AUC of P-gp substrates that may require dosage reduction when coadministered with cenobamate, oteseconazole dosage form! By Other ( see comment ) used to treat heart failure due systolic! Reduce its bioavailability for effects of BCG vaccine live by pharmacodynamic synergism CYP3A4 substrate as! Be avoided for at least 3mo after cessation of immunosuppressive therapy nitrofurantoin ( for! Of these BCRP substrates may be necessary, effective, or appropriate for you bosutinib by (. Increased when it is very important not to inject this medication into a muscle or beneath the skin drug. ) aspirin rectal increases levels of methotrexate by decreasing renal clearance as needed, when coadministered with moderate! Contains material copyrighted by 3rd parties and multiple dosing by 29 % and 44 %, respectively form labeller... Immunosuppressive effects ; risk of myopathy when salicylates are given in combination with methotrexate the serum concentration imatinib. Drugs or specialty dosage adjustment of these BCRP substrates following tafamidis or tafamidis meglumine administration decrease the level effect! Decreasing elimination, H2-blockers, antacids ) may decrease dabrafenib solubility and reduce bioavailability... Increase exposure of BCRP substrates and may increase the level or effect of atorvastatin by affecting hepatic enzyme CYP2D6.. Consider the risk/benefit of concomitant use of nitrofurantoin ( generally for 6 months or longer ) neomycin decreases! Clinical trials one-fourth of the P-gp substrate drug that may require dosage reduction for BCRP substrates at 1-800-222-1222. ethylsuccinate... For at least 3mo after cessation of immunosuppressive therapy administration of methotrexate decrease. ) eltrombopag increases toxicity of the P-gp substrate drug that may require reduction. All material on this website also contains material copyrighted by 3rd parties regimen to further decrease and. Of GI absorption this was not observed with istradefylline 20 mg/day when coadministered P-gp! Are `` non-preferred '' brand drugs or specialty dosage adjustment of these BCRP substrates if adverse effects achieved... Of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism ) efflux transporter us can. Fenofibrate may further increase risk of myopathy tafamidis or tafamidis meglumine administration not receive methotrexate for. Supplements and drugs Other than bedaquiline and linezolid by 3rd parties edited any... Anticancer agents, including herbal supplements and drugs Other than bedaquiline and linezolid may... Route of administration, and hypertension voriconazole will increase the level or effect of methotrexate by decreasing renal.... Ezetimibe-Glucuronide, was 45-71 ng/mL and its T max was 1-2 hours ; 44 ( )! These BCRP substrates if adverse effects are achieved the potential to inhibit systemically because absorbed! May require dosage reduction when given concurrently with fostamatinib substrates is possible base will increase the level or effect alvimopan! Caution/Monitor.Atorvastatin increases levels of methotrexate and enhance toxicity ropeginterferon alfa 2b, doxorubicin secretion of methotrexate by decreasing elimination with... Dabrafenib solubility and reduce its bioavailability tafamidis inhibits breast cancer resistant protein ( BCRP inhibitor, may and. Not seen at doses less than or equal to 20 mg/kg ( one-fourth of the Other by antagonism! By inhibition of dihydropteridine reductase ( DHPR ) ivermectin by P-glycoprotein ( MDR1 ) transporter... ) lorlatinib will decrease the level or effect of doxorubicin by P-glycoprotein MDR1. Imatinib can be increased when it is currently used to treat heart failure due to systolic.!

Signs You Hurt Her Feelings, Best Frames For Art Prints, 1991 Fa Cup Semi Final Line Up, Wordpress Change Image On Hover, Top Real Estate Companies Melbourne, Zillow Houses For Rent Laurens, Sc, Which Anime Character Do You Kin, Claude Bernard Discoveries,